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A B S T R A C T
Background: Internet-delivered interventions can provide remarkable opportunities in addressing breast cancer
survivors' unmet support care needs, as they present an eﬀective strategy to improve care coordination and
provide access to eﬃcacious, cost-eﬃcient and convenient survivorship care. Nevertheless, research focusing on
improving survivors' psychosocial needs using internet-based tools is scarce and its practical implementation is
limited.
Objectives: To study the acceptability, feasibility, eﬃcacy and cost-eﬀectiveness of iNNOVBC, a 10 weeks guided
internet-delivered individually-tailored Acceptance and Commitment Therapy (ACT)-inﬂuenced cognitive be-
havioural (CBT) intervention developed to improve mild to moderate anxiety and depression in Breast cancer
survivors when compared to treatment as usual (TAU) in a waiting list control group (WLC).
Methods: A two-arm, parallel, open label, multicentre, waiting list randomized controlled trial will be conducted
to investigate the eﬃcacy and cost-eﬀectiveness of INNOVBC. The primary outcomes in this research will be
anxiety and depression. Secondary outcomes will include psychological ﬂexibility, fatigue, insomnia, sexual
dysfunction and Health Related Quality of Life (HRQoL).
Ethical approval: This study has been reviewed and approved by Comissão Nacional de Proteção de Dados; Instituto
Português de Oncologia do Porto Francisco Gentil; Unidade Local de Saúde de Matosinhos, EPE; Centro Hospitalar de
São João and Ordem dos Psicólogos ethical committees.
Expected results: It is anticipated that iNNOVBC will show to be an eﬃcacious and cost-eﬀective program in
improving the outcomes of interest in this study, as opposed to a WLC under TAU. The results of this research
will be published in accordance with CONSORT-EHEALTH guidelines.
Conclusions: This study will inform on the acceptability, feasibility, eﬃcacy and cost-eﬀectiveness of iNNOVBC,
in improving psychosocial outcomes in breast cancer survivors when compared to TAU in a WLC. Its conclusions
will contribute to understand the idiosyncrasies of designing and implementing internet-delivered interventions
in breast cancer survivors.
Trial Registration code: INNOVBC (NCT03275727).
1. Background
Breast cancer is the second most common cancer in the world and
the most frequent among women, with 2.1 million incident cases
estimated in 2018 and 6.9 million women living with cancer within
5 years of diagnosis. Breast cancer is the fourth cause of death from
cancer overall and the leading cause of cancer deaths for women.
However, due to major advances in early diagnosis, improvements in
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treatment and cancer management, survival has increased steadily over
time in the developed countries. In Portugal, particularly, 5-year pre-
valence is estimated to be 26,329 in 2018, which translates into a high
and growing number of breast cancer survivors in the country (Bray
et al., 2018). Breast cancer survivors are a heterogeneous group in
terms of personal and tumour characteristics, as well as treatments
performed. Most literature focusing on Health-related Quality of Life
(HRQoL) reports high levels of functioning and HRQoL in breast cancer
survivors (Mols et al., 2005). Nevertheless, a “signiﬁcant minority” of
20%–30% of survivors, experience sequelae of treatment, late eﬀects
and unmet support care needs, including physical, psychosocial or
practical problems, that can occur immediately to several years after
primary treatment ends and cause clinically signiﬁcant levels of dis-
ruption (Beckjord et al., 2016). Among the potential psychosocial late
and long-term eﬀects breast cancer survivors may experience are: an-
xiety (Burgess et al., 2005; Hodgkinson et al., 2007); depression
(Burgess et al., 2005; Maass et al., 2015; Kim et al., 2008); fear of
cancer recurrence (Simard et al., 2013; Ellegaard et al., 2017; Koch
et al., 2014); cancer related fatigue (Kim et al., 2008; Goldstein et al.,
2012; Abrahams et al., 2016; Reinertsen et al., 2017); sleeping pro-
blems (Lowery-Allison et al., 2017) and sexual dysfunction (Boquiren
et al., 2016; Panjari et al., 2011; Paterson et al., 2016; Raggio et al.,
2014). Reports on the prevalence and degree to which these diﬃculties
aﬀect breast cancer survivors vary in the literature.
Recent reviews by Zainal et al. (2013) and Maass et al. (2015) de-
termined that the prevalence of depression and anxiety in breast cancer
survivors varies from 6% to 56% and 17,9% to 33,3%, respectively.
When compared to the general female population, the prevalence of
depression was found to be higher and persistent over> 5 years after
diagnosis, while the prevalence of anxiety was considered equivalent to
results exhibited by the general female population. On the contrary, a
study by Hodgkinson et al. (2007) aiming at identifying long-term
outcomes and supportive care needs in disease-free breast cancer sur-
vivors, documented higher rates of anxiety 2–10 years after diagnosis,
but depression scores consistent with age-adjusted community pre-
valence rates. Moreover, clinically anxious survivors reported over
three times as many unmet needs as those with no anxiety. The ﬁeld of
most frequently reported unmet needs was existential issues and the
most prevalent unmet need identiﬁed in this research was related to
managing concerns about the cancer coming back, which is consistent with
literature ﬁndings focusing on fear of cancer recurrence (Ellegaard
et al., 2017). Fear of cancer recurrence is highly prevalent among breast
cancer survivors (rates ranging from 52% to 86%) and seems to remain
stable over the survivorship trajectory (Simard et al., 2013; Koch et al.,
2014). Higher levels of fear of cancer recurrence have been associated
with younger age, psychological distress, lower HRQoL, presence and
severity of physical symptoms (Simard et al., 2013), higher health costs
and lower surveillance rates, compromising breast cancer survivors
health outcomes (Thewes et al., 2012).
Along with fear of cancer recurrence, cancer related fatigue has
been reported as one of the most frequent, persistent and disruptive
adverse events experienced by breast cancer survivors. Prevalence rates
vary from 25% to 99% depending on the type of treatment received and
method of assessment (Bower, 2014), and although its highest pre-
valence is during chemotherapy (CT), around 30% of breast cancer
survivors experience enduring cancer related fatigue symptoms more
than ﬁve years into survivorship (Reinertsen et al., 2017). A recent
meta-analysis (Abrahams et al., 2016) focusing on cancer related fa-
tigue related risk factors identiﬁed higher disease stages, CT and re-
ceiving the combination of surgery, radiotherapy (RT) and CT with or
without hormone therapy (HT) as risk factors of severe fatigue in this
population. Conversely, having a partner, performing surgery alone or
surgery plus RT decreased the risk. Other studies have found an asso-
ciation between fatigue and pre-treatment fatigue (Bower, 2014), pain
(Kim et al., 2008), dyspnea, depression, physical inactivity and high
body mass index (Bower, 2014), signiﬁcant disability and health care
utilization (Goldstein et al., 2012) and poor HRQoL (Kim et al., 2008).
Sleep disturbance is also a long-term concern in this population.
Experienced over 5–10 years post-treatment it has been associated with
cancer related fatigue, depression and anxiety (Otte et al., 2010), lower
HRQoL, greater severity of pain, fear of cancer recurrence and in-
creased vasomotor symptoms (Lowery-Allison et al., 2017). Its pre-
valence is higher in breast cancer survivors than in the general popu-
lation and other cancer groups ranging from 38% to 73% (Lowery-
Allison et al., 2017; Otte et al., 2010; Carpenter et al., 2004).
Another major, but often neglected, problem breast cancer patients
may experience during survivorship is sexual dysfunction. Breast cancer
treatments and associated side-eﬀects can impair diﬀerent areas of
sexual function via a myriad of mechanisms, such as disrupting ovarian
function, body image, intimacy and relationships (Paterson et al., 2016;
Seav et al., 2015). Sexual dysfunction prevalence rates vary in the lit-
erature, ranging from 45% to 83% (Boquiren et al., 2016; Panjari et al.,
2011; Safarinejad et al., 2013) being higher than in the general female
population and persisting for several years after treatment completion
(Raggio et al., 2014) compromising survivors' HRQoL (Safarinejad
et al., 2013). Breast cancer survivors of younger age; presenting nega-
tive or body image disturbance, low perceived sexual attractiveness,
poorer marital/relationship satisfaction or relationship distress, facing
partner's fear of sexual intercourse, depression, psychological distress,
vasomotor symptoms, lymphedema, weight gain, tiredness and pain;
having performed a combination of RT, CT and HT, treatment with
aromatase inhibitors, and bilateral mastectomy, are at higher risk of
developing sexual dysfunction (Boquiren et al., 2016; Panjari et al.,
2011; Raggio et al., 2014; Safarinejad et al., 2013).
Given the above, addressing breast cancer survivors' supportive care
needs is key to improve their adjustment and well-being (Hodgkinson
et al., 2007). However, providing such care depends on the ability of
the healthcare systems to deliver comprehensive, highly coordinated,
patient-centred care, which may prove diﬃcult to operationalize in a
context of competing priorities and constrained health and social care
budgets. Additionally, many survivors will no longer attend follow-up
appointments as often as in the initial stages of survivorship and in-
novative intervention strategies capable of reaching those in need and
controlling costs without diminishing quality of service such as, inter-
ventions delivered by primary care workers, the Internet and self-help
groups may be required (Hodgkinson et al., 2007). In this context, in-
ternet-delivered interventions, can provide remarkable opportunities in
overcoming some of the aforementioned constraints, as presenting an
eﬀective strategy to improve care coordination and provide access to
eﬃcacious, cost-eﬃcient and convenient breast cancer survivorship
care (Post and Flanagan, 2016).
Internet-delivered interventions consist of self-help interventions,
implemented as a prescriptive online program operated via a secure
platform/website or mobile application (app) and used by consumers
seeking health and mental-health related assistance (Andersson et al.,
2008; Andersson and Titov, 2014). Internet interventions are often
based on psychotherapy models - most commonly cognitive-beha-
vioural therapy (CBT) – adopt a schedule and length that is similar to
face to face treatment protocols (usually, 5 to 15 weeks) and can in-
clude a guided or unguided structure, involving or not therapist/clin-
ician contact. Guided interventions can be further divided into those
including synchronous interaction (e.g. real-time contact via telephone,
video, or messenger services), asynchronous interaction (e.g. encrypted
e-mail communications) or both types of interaction with patients. The
amount of time therapists devote to work with patients varies between
studies, but is often signiﬁcantly reduced when compared to face-to-
face psychological treatments (Andersson et al., 2008; Andersson and
Titov, 2014). The beneﬁcial impact of guided internet-delivered inter-
ventions has been shown in several studies (Andersson and Cuijpers,
2009). Nevertheless, automated reminders and other features may be
included in guided interventions and the type and amount of contact
between patient and therapist should be adjusted to the condition in
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question, since some conditions require more guidance and support
than others (Andersson, 2016).
During treatment, patients login regularly to a secure website,
where the online environment is similar to online banking or an e-
learning platform. Systems are encrypted, and double authentication
procedures and one-time passwords are required at login (Andersson,
2016). Once logged in, patients have access to text, audio and/or video
content, interactive programs and e-mail based individualized instruc-
tions that may be read/streamed online or downloaded/printed. The
online materials are organized into a series of lessons or treatment
modules (Andersson and Titov, 2014) – the equivalent to a face-to-face
psychotherapy “session”. Treatment usually starts with psychoeduca-
tion content, continues with modules that are based on treatment
manuals and established psychotherapy methods for speciﬁc disorders
(Carlbring et al., 2011) and ends with a relapse/prevention module. It
can include ﬁxed modules and follow a linear structure or comprise
optional modules and be individually-tailored. In the latter case,
treatment is organized according to a case formulation, client pre-
ferences and/or characteristics and a transdiagnostic perspective is
frequently adopted. Tailored interventions are particularly relevant
when addressing comorbidity or overlapping conditions, since the pa-
tient has the power of determining which problems or symptoms are
more urgent to deal with (Carlbring et al., 2011). On the course of
treatment, homework assignments are prescribed. Patients are expected
to complete those assignments before the next treatment module is
made available and the use of mobile technology enables real-time
submission of homework assignments. Furthermore, during treatment,
patients are asked to complete computer administered questionnaires
adequate to their condition and appropriate to monitor their progress,
safety and outcomes. The addition of other interactive features such as,
discussion forums, messaging services (chats), video-conference,
quizzes and SMS reminders is also a possibility (Andersson and Titov,
2014; Andersson, 2016).
Over the last years, various controlled trials, systematic reviews and
meta-analysis have been published supporting the eﬃcacy and eﬀec-
tiveness of internet interventions (Andersson and Cuijpers, 2009;
Andersson, 2016; Richards and Richardson, 2012; Olthuis et al., 2016;
Barak et al., 2008). They have been found to be more eﬀective than
treatment as usual (TAU) or as eﬀective as face-to-face therapies for a
wide range of disorders, namely anxiety and depression. Nevertheless,
research in the breast cancer survivorship setting is scarce. Most studies
focusing on this population reported on the eﬃcacy of CBT protocols
(Amidi et al., 2018; Hummel et al., 2017; Zhang et al., 2017). A recent
integrative review (Post and Flanagan, 2016) identiﬁed 15 studies on
the matter, with 46,66% of the studies being published from 2015
onwards. Of these, 5 studied CBT and psychosocial interventions
(Carpenter et al., 2014; Damholdt et al., 2016; Bruggeman Everts et al.,
2015; Lepore et al., 2014; Berg et al., 2015); 3 implemented physical
activity and lifestyle interventions (De Cocker et al., 2015; Lee et al.,
2014; McCarroll et al., 2015); 2 addressed symptom management
(Wheelock et al., 2015; Bock et al., 2012) and; 5 were pilots and ex-
ploratory studies (Haq et al., 2013; Hill-Kayser et al., 2013; Johnson-
Turbes et al., n.d.; Pauwels et al., 2013; Wen et al., 2012). Self-eﬃcacy,
empowerment, working memory, reduced fatigue, distress (Carpenter
et al., 2014; Damholdt et al., 2016; Bruggeman Everts et al., 2015; Berg
et al., 2015), depression (Lepore et al., 2014), exercise frequency,
weight change, fruit/vegetable intake (De Cocker et al., 2015; Lee et al.,
2014; McCarroll et al., 2015), reported time on symptom management
(Wheelock et al., 2015; Bock et al., 2012), patient satisfaction, usability
and acceptability (Haq et al., 2013; Hill-Kayser et al., 2013; Johnson-
Turbes et al., n.d.; Pauwels et al., 2013; Wen et al., 2012) were the
primary outcomes in these studies. Overall, the ﬁndings of these re-
search suggest that internet-delivered survivorship interventions are
feasible and acceptable to breast cancer survivors and most studies
reported improvements in their intended outcomes. However, many
limitations can be appointed to these studies (Post and Flanagan, 2016):
many studies lacked on a control or comparison group; there was lim-
ited information on the cost-eﬀectiveness of the internet-interventions
and; none of the studies reported on longitudinal patient outcomes such
as HRQoL. These limitations highlight the need for additional research
in this ﬁeld.
Within the Third Wave of cognitive behavioural therapies,
Acceptance and Commitment Therapy (ACT), due to its model of
healthy adaptation to diﬃcult circumstances and transdiagnostic ap-
proach, may be particularly useful in addressing the high levels of
psychological and medical comorbidities that manifest in cancer po-
pulations (Fashler et al., 2018). ACT's eﬃcacy has been studied in
several conditions, namely anxiety, depression and chronic pain and its
application to the cancer setting is increasing (Hulbert-Williams et al.,
2015). More recently, ACT-based internet-interventions are emerging
and some positive preliminary results have been published (Low et al.,
2016; Köhle et al., 2015; Arch and Mitchell, 2016; Mujcic et al., 2018;
Köhle et al., 2017). Nevertheless, stronger evidence of eﬃcacy and cost-
eﬀectiveness is needed. Thus, the present research intends to contribute
to close the abovementioned research gaps by assessing the feasibility,
eﬃcacy and cost-eﬀectiveness of iNNOVBC – a 10 weeks guided in-
ternet-delivered individually-tailored ACT-inﬂuenced CBT intervention
developed to improve mild to moderate anxiety and depression in
Breast cancer survivors when compared to TAU in a waiting list control
group (WLC).
2. Objectives and hypotheses
This research aims at exploring the acceptability, feasibility, eﬃ-
cacy and cost-eﬀectiveness of iNNOVBC - a 10 weeks guided internet-
delivered individually-tailored ACT-inﬂuenced CBT intervention de-
veloped to improve mild to moderate anxiety and depression in Breast
cancer survivors when compared to TAU in WLC. This research also
aims at assessing INNOVBC's eﬃcacy in improving psychological ﬂex-
ibility, fatigue, insomnia, sexual dysfunction and HRQoL in breast
cancer survivors when compared to TAU in a WLC; and examining
iNNOVBC's cost-eﬀectiveness, from a societal perspective.
We hypothesise that iNNOVBC will prove to be more eﬃcacious in
improving the above-mentioned outcomes in breast cancer survivors
when compared to TAU in a WLC. We also expect iNNOVBC to show to
be a cost-eﬀective method to deliver psychosocial care to breast cancer
survivors when compared to TAU in a WLC.
3. Methods
3.1. Study design
A two-arm, parallel, open label, multicentre, waiting list rando-
mized controlled trial will be conducted to investigate the eﬃcacy and
cost-eﬀectiveness of iNNOVBC when compared to TAU in a WLC. A
Pilot study, mirroring the conditions of this trial will be performed to:
evaluate the feasibility of the parent study; identify potential weak-
nesses of the study design; test the structure, format and content of the
study intervention; test the data collection process; and obtain pre-
liminary data for the primary outcome measures, in order to attest/
correct the previous calculated sample size. Results from this Pilot study
should be appraised after randomization of 30 participants to the study
and inform execution of the main trial (c.f. Fig. 1). If the assessment
does not indicate changes to be made in the study design or procedures,
the pilot study will proceed to the main study. An economic evaluation
of iNNOVBC will be undertaken from a societal perspective.
3.2. Study population
The study population includes female individuals diagnosed with
primary breast cancer, who have completed primary adjuvant treat-
ment from 6 months up to 10 years before enrolling in the study and
C. Mendes-Santos, et al. Internet Interventions 17 (2019) 100236
3
Fig. 1. Study design.
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show no evidence of disease. For this project, the sample will be col-
lected in Portugal. The following criteria should be used to check
eligibility for participation in the study (c.f. Table 1).
3.3. Research sites
To increase the generalizability of results, this project will adopt a
multicentric design. Sites invited to participate were selected due to its
treatment standards and resources.
3.4. Study intervention
iNNOVBC is a guided, self-management, individually-tailored, in-
ternet-delivered ACT-inﬂuenced CBT program composed of 10 treat-
ment modules, namely 5 mandatory modules – Introduction: Living with
breast cancer and beyond; Depression; Anxiety, worries and fear of recur-
rence; Relaxation and; Conclusion: Key points summary and Planning for
the future - and 5 optional modules – Behavioural activation Parts I and II;
Sleep problems; Fatigue and; Interpersonal relationships, sex and intimacy -
to be completed from 5 to 10 weeks. Its structure and content build on
prior research interventions developed by the Department of
Behavioural Sciences and Learning at Linköping University (Carlbring
et al., 2011; Jasper et al., 2014; Andersson et al., 2013; Buhrman et al.,
2013) that have been considered eﬀective for various outcomes such as
depression, anxiety, chronic pain and tinnitus. The applicable pre-
viously available content was translated from Swedish and English to
Portuguese and validated by external experts. Additional content was
developed considering several peer-reviewed sources (NCCN, 2017a;
NCCN, 2017b; NCCN, 2017c; Andersson, 2014; Hayes et al., 2012) and
validated by multidisciplinary external experts. The program adopts a
transdiagnostic structure, featuring treatment strategies considered re-
levant for the diﬀerent conditions at interest in this research. Its central
components are: psychoeducation, acceptance, cognitive defusion,
connecting with values, committed action, exposure, behavioural acti-
vation and relaxation. By cultivating the abovementioned processes
through experiential exercises, metaphors and homework assignments
considered appropriate for breast cancer survivors, the intervention
aims at diminishing patients symptoms and increasing psychological
ﬂexibility. For participants selecting the optional modules, the men-
tioned core processes will be adjuvated by one or more of the following
techniques: sleep management, energy conservation techniques, pro-
blem solving and sensate focusing.
At the onset of the intervention participants should tailor their
treatment with the support of their assigned therapist and according to
their baseline assessment. The completion of a module by the partici-
pant, triggers the access to the next. Each module takes approximately
60 min to complete and comprises short texts, images, videos, audio-
ﬁles and calendar features matching the modules' themes; quizzes; ACT
and CBT based exercises, homework assignments and respective
worksheets. Professional feedback and guidance will be provided by
certiﬁed psychologists and psychology trainees under supervision,
asynchronously, and once a week, unless a supplementary e-consulta-
tion is requested by the participant. Integrated two-way communication
features such as e-mail, chat, SMS and video-conference will support
this process. Therapists will be instructed to use approximately 15 min
per participant per week. This period should be used to monitor and
assess participants' progress, read messages and write answers.
Therapists feedback should be based on the following guidelines
(Paxling et al., 2012): validation of participants' work and reported
diﬃculties; problem-solving and clariﬁcation on the implementation of
treatment techniques; therapeutic alliance bolstering; task prompting;
progress reinforcement and; encourage continued work. A referral al-
gorithm will be in force throughout the program ensuring participants
referral to the study sites respective Psychiatric/Psycho-oncology De-
partment in case of acute aggravation of their condition. The inter-
vention will be delivered via iTerapi, a web-based treatment platform
developed at Linköping University. Further details on the platform
features, including its security features, are described elsewhere
(Vlaescu et al., 2016).
3.4.1. Treatment as usual (TAU)
In this study, TAU corresponds to the routine care participants
would receive when diagnosed with any of the conditions under study
at the recruitment sites. Thus, TAU can vary from site to site and among
participants and is likely to include pharmacologic treatment and/or
psychosocial support. The type of TAU received will be monitored
through patients' records and self-report measures (e.g. TIC-P). WLC
participants will be informed that they are free to access any form of
support/TAU during the study. They will also be instructed to seek
professional support, in case they experience symptomatic deterioration
Table 1
Eligibility criteria INNOVBC RCT.
Inclusion criteria • Signed written informed consent.
• Age≥ 18 years;
• Ability to read and write in Portuguese.
• History of histologically or cytologically conﬁrmed breast cancer with no evidence of metastatic disease.
• An interval≥ 6 month from primary adjuvant treatment completion (surgery, chemotherapy and/or radiotherapy), except for hormonal therapy.
• Clinically signiﬁcant symptoms of mild to moderate anxiety (GAD-7 scores from 5 to 14) and/or moderately to moderately severe depression (PHQ-9 scores
from 6 to 14). Patients can or not present clinically signiﬁcant symptoms of insomnia, fatigue or sexual dysfunction.
• Ongoing regular psychoactive medication only accepted if dosage has been stable during the last 3 months.
• Daily access to the Internet by computer and/or smartphone.
• Ability to use a computer and/or smartphone and the internet.
• No participation on any other interventional study or clinical trial.
Exclusion criteria • Age≤ 18 years;
• Inability to co-operate and give informed consent.
• Breast cancer not histologically or cytologically conﬁrmed.
• History of other malignancy within the last 5 years.
• Metastasized breast cancer.
• Current severe, uncontrolled systemic disease or mental disorder.
• Absence of clinically signiﬁcant symptoms of mild to moderate anxiety (GAD-7 scores < 5) and/or moderately to moderately severe depression (PHQ-9
scores <5) or presence of severe anxiety (GAD-7 > 15) and severe depression (PHQ-9 > 15). The presence of clinically signiﬁcant symptoms of insomnia,
fatigue or sexual dysfunction as stand-alone conditions does not fulﬁl the necessary requirements to be enrolled in the trial.
• Parallel ongoing psychological treatment.
• Ongoing regular psychoactive medication if dosage has been changed during the last 3 months.
• No access to the internet.
• Inability to use a computer and/or smartphone and the internet.
• Parallel ongoing participation in other interventional study or clinical trial.
• Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol.
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or other diﬃculties over the course of the study. Participants in the
WLC will be oﬀered the same treatment protocol applied to the ex-
perimental group after completion of the program (approximately
3 months from baseline).
3.5. Outcome variables and outcome measures
All variables and assessments will be collected online and via
iTerapi. Outcome measures selection was based on psychometric
properties, feasibility and frequency of use in both oncology and in-
ternet interventions domains to ensure data comparability. A compi-
lation of the outcome measures to be used in this research is available in
Table 2.
3.5.1. Socio-demographic and medical information
The following socio-demographic and medical information vari-
ables will be assessed in this study: Age; education; marital status; oc-
cupation; area of residence; distance between residence and cancer
centre; comorbidities; history of prior psychological/psychiatric treat-
ment; menstrual status; body mass index (BMI); BC diagnosis date
(biopsy or cytology date); type of BC; date of BC surgery; number of BC
related surgeries; type of surgery; breast reconstruction; history of
neoadjuvant treatment; neoadjuvant treatment start and end dates; type
of neoadjuvant treatment; history of adjuvant treatment; adjuvant
treatment start and end dates; type of adjuvant treatment; TNM status;
ECOG; and concomitant psychoactive medication. These variables will
be collected using a customized, brief, self-report, socio-demographic
and clinical questionnaire developed for this purpose. Missing clinical
data will be provided by the local study team at each site and will be
collected through the analysis of patients' ﬁles.
3.5.2. Primary outcomes and measures
The primary outcome variables in this research are anxiety and
depression. The Patient Health Questionnaire (PHQ-9) (Torres et al.,
2016) and Generalized Anxiety Disorder Scale (GAD-7) (Sousa et al.,
2015) will be used to measure anxiety and depression, respectively,
throughout the study.
3.5.3. Secondary outcomes and measures
Psychological ﬂexibility, fatigue, insomnia, sexual dysfunction and
HRQoL are considered secondary outcome variables in this research.
Changes in ACT-processes will be measured with Cancer Acceptance
and Action Questionnaire (Cancer AAQ) (Arch and Mitchell, 2016).
Fatigue, insomnia and sexual dysfunction will be evaluated with the
Brief Fatigue Inventory (BFI) (Mendoza et al., 1999), Insomnia Severity
Index (ISI) (Bastien et al., 2001) and Female Sexual Function Index
(FSFI) (Pechorro et al., 2009) respectively and EORTC QLQC30 and
QLQBR23 corresponding items. HRQoL will be measured with QLQC30
(Pais-Ribeiro et al., 2008), QLQBR23 (Sprangers et al., 1996) and
EuroQol-5D-5 L (Ferreira et al., 2016).
3.5.4. Exploratory outcomes and measures
Participants' attitudes towards internet interventions, breast cancer
patients' unmet support needs, and intervention feasibility and cost-
eﬀectiveness will also be explored. Participants' attitudes towards in-
ternet interventions will be investigated with ATIIS – a short, self-report
questionnaire developed in the context of this research, to assess par-
ticipant's perceived usefulness, ease of use and attitudes towards in-
ternet interventions. Due to the scarcity of adequate instruments to
evaluate this construct in the target population, a customized ques-
tionnaire was developed based on a literature review (Topooco et al.,
2017; Schröder et al., 2015; Jansen et al., 2015) and enquiries of
healthcare professionals. Its psychometric properties will be assessed
during this research.
Breast cancer patients' unmet support care needs will be assessed
with the Supportive Care Needs Survey Questionnaire (SCNS-SF34)
(Boyes et al., 2009).
Intervention feasibility will be assessed considering: demand (ex-
pressed by participants' unmet needs, recruitment rates and initial
iNNOVBC uptake), acceptability (given by BC survivors' attitudes to-
wards internet interventions, the perceived appropriateness of the
treatment program and participants' satisfaction with iNNOVBC), im-
plementation (analysed based on adherence to iNNOVBC/treatment
modules completion, retention and attrition rates, amount and type of
resources needed to implement the program and factors aﬀecting the
implementation), practicality (reporting on usability, eﬃcacy, and cost-
eﬀectiveness of iNNOVBC), integration (evaluating the perceived ﬁt
within diﬀerent sites and potential costs to sites and policy bodies) and
expansion (based on healthcare providers' attitudes towards internet
interventions, perceived ﬁt with organizational goals and culture, po-
sitive or negative eﬀects on sites and potential disruption due to ex-
pansion of the program). iNNOVBC speciﬁc feasibility measures in-
clude: recruitment rates, screening failure logs, iNNOVBC initial uptake
rates, adherence rates, attrition and retention rates, iTerapi users' ac-
tivity logs and single-item questions assessing participants' perceived
appropriateness, usability and satisfaction with iNNOVBC treatment
modules and program. ATIIS and SCNS-SF34 results, eﬃcacy and cost-
eﬀectiveness analysis will also be used to assess iNNOVBC demand,
practicality, integration and expansion feasibility components.
Finally, iNNOVBC associated costs will be assessed based on direct
medical costs - all healthcare utilization of the participants will be
collected, regardless of the cause or reason for using the service (e.g.,
visits to general practitioner, to mental health care, hospital admis-
sions, etc.) - direct non-medical costs (e.g., direct out-of-pocket ex-
penses such as, travelling, lodging and home services) and productivity
losses (absenteeism and presenteeism). These variables will be collected
using the Questionnaire on Medical consumption and Productivity
losses associated with Psychiatric Illness (TIC-P) (Bouwmans et al.,
2013).
3.6. Study procedures
3.6.1. Compliance with laws, regulations and ethical requirements
This study will be conducted in accordance with the International
Conference on Harmonisation (ICH) E6 Guideline for Good Clinical
Practice (GCP), the Declaration of Helsinki (October 1996) and the
following Portuguese Decree-laws: Lei n.° 67/98, de 26 de Outubro (Lei
de Protecção de Dados Pessoais); Lei n°. 21/2014 (Lei da Investigação
Clínica), de 16 de Abril; Regulamento n.° 258/2011 (nos termos do artigo
77.° do Estatuto da Ordem dos Psicólogos Portugueses, aprovado pela Lei n.°
57/2008, de 4 de Setembro, a Ordem elabora, mantém e actualiza o Código
Deontológico da Ordem dos Psicólogos Portugueses); and Deliberação n.°
1704/2015 (Deliberação da Comissão Nacional de Protecção de Dados
Aplicável aos tratamentos de dados pessoais efectuados no âmbito de
Investigação Clínica). This study will also comply with EU Regulation
2016/679 of The European Parliament and of the council of 27 April
2016 on the protection of natural persons with regard to the processing
of personal data and on the free movement of such data.
This research protocol has been reviewed and approved by
Comissão Nacional de Proteção de Dados; Instituto Português de
Oncologia do Porto Francisco Gentil, Unidade Local de Saúde de
Matosinhos, EPE; Centro Hospitalar de São João and Ordem dos
Psicólogos ethical committees.
3.6.2. Study initiation
The study will be initiated in January 2019. The study duration will
be approximately 22 months including a recruitment period of ap-
proximately 6 months.
3.6.2.1. Study initiation visit and study therapists' training. A study
initiation visit will be performed to present the research protocol,
train the local study teams and adjust the study procedures to sites'
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idiosyncrasies. A training course targeting the study therapists will be
delivered prior the onset of the recruitment period with the purpose of
harmonizing knowledge between therapists included in the study team.
This course will focus on BC clinical and psychosocial aspects, ACT,
internet-delivered psychosocial programs, good clinical practices, the
research protocol, the study Instruments and iTerapi. The course will be
taught by certiﬁed oncologists and psychologists, who are also co-
investigators in this study and should be delivered online and/or in loco
over 12 h.
3.6.3. Recruitment
Potential study participants will be identiﬁed, with the support of
local study team members, by reviewing cancer registration databases
and patient ﬁles at each site. While long term follow-up patients will be
mainly invited to participate via post mail since they may not have an
appointment scheduled at the sites during the recruitment period,
participants ongoing treatment or short-term follow up will be invited
to participate at the study sites during medical, surgical and multi-
disciplinary appointments. In the latter case, patients will be ap-
proached by their clinician or by other element of the local study team,
trained for this purpose. Subjects requesting to participate, but not di-
rectly invited by the study team (e.g., self-referral patients ﬁnding
about the study through the study website or by a third person, such as
other participant, etc.) may be allowed to participate if their treatment/
follow-up is ensured by any of the participating sites.
3.6.3.1. Consent process. A written informed consent must be obtained
for all participants and prior to any study speciﬁc assessments and
procedures are performed. Regardless of the implemented recruitment
method – post mail or face-to face – the ﬁrst contact should be
performed by a local study team member to obtain patients'
permission to be approached by the researchers and copies of the
Study Information Sheet and Informed Consent Form (ICF) should be
provided for analysis. After reading the study documents, if a patient is
interested in participating in the trial, an appointment – face to face or
teleconference/videoconference - should be scheduled with the purpose
of detailing the study objectives and procedures, answering to queries
raised by the patient, conﬁrming her interest in participating,
determining eligibility and signing the ICF. The signature of the ICF
should be obtained, whenever possible, in the presence of one of the
research team members. For patients recruited via post mail and/or
refusing to meet the researchers at the study site, the ICF may be
returned via post mail. After the signature of the ICF, study procedures
may be initiated. If and whenever an updated version of the ICF is
enforced, a reconsent must be obtained. ICF will be stored at the
Clinical Research Unit or Breast Clinic of each site by a Clinical
Research Coordinator or Clinical Nurse Manager, respectively.
3.6.3.2. Participants recruitment strategies. In order to guarantee the
success of this research, the following recruitment strategies should be
applied: an Invitation ﬂyer describing the study to potential participants
should be made available at the reception areas, examination rooms
and multidisciplinary meeting rooms at the study sites and at BC
patients associations; a web banner linking to the study website should
be advertised in the study sites' website, whenever possible; healthcare
providers such as, nurses, psychologists, oncologists, surgeons and
radiation oncologists should be informed about the study and be
encouraged to refer patients meeting the eligibility criteria; and a
reminder telephone contact should be performed two weeks after the
ﬁrst contact with the patient. All advertisement material targeting the
public should comply with study sites' regulations and the Portuguese
regulation on the matter as it is enforced in articles 2°, 40° and 42° of
the Decree-law n°21/1014, de 16 de Abril.
3.6.4. Screening and pre-assessment procedures
Following the participants' consent to participate in the study, the
screening procedures should be initiated. Participants fulﬁlling the in-
itial screening criteria should be invited to a diagnostic interview, to
establish their eligibility for the study. The Mini-International
Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) will be used
for this purpose. MINI should be performed by a certiﬁed psychologist
or by psychologist students/trainees participating under the supervision
of a certiﬁed psychologist. Subjects diagnosed with severe mental dis-
orders or suicide risk will be referred to the respective Psychiatric/
Psycho-oncology Department at the study sites. Baseline pre-assessment
procedures should be completed online, via iTerapi, starting from the
day ICF is signed. Access to a computer or mobile device should be
provided for patients completing the pre-assessment at the sites.
3.6.5. Enrolment and randomization
Following registration, randomization procedures will be conducted
in two steps. Firstly, the method of minimization will be applied to
ensure treatment arms are balanced with respect to the severity of
anxiety and depression, as well as for the number of patients in each
group. A random element will be incorporated, and allocation will be
concealed. Subsequently, participants in the experimental arm will be
randomly assigned to one of the four therapists providing support to
participants during the trial. Simple randomization will be used at this
stage. Randomization procedures will be performed by an independent
statistician collaborating with the research team and that has no contact
with the study subjects. A computerized program will be used in these
procedures. After randomization, all participants will receive an e-mail
with a link to login into iTerapi and get to know the outcome of ran-
domization: Arm A – Experimental condition or Arm B – WLC condi-
tion. Participants in Arm A will receive immediate access to iNNOVBC,
while WLC will receive access to the intervention approximately
3 months after the baseline measurement. WLC will undergo a second
baseline assessment to reconﬁrm eligibility for iNNOVBC prior the
onset of the intervention and follow the same protocol measurements as
experimental condition subjects.
3.6.6. Study intervention and assessments
After randomization, participants from both study arms will main-
tain access to the platform. While WLC will sustain the same access
level obtained during the screening phase (e.g., study general in-
formation, baseline measures, etc.) and be informed about their inter-
vention start date, participants assigned to Arm A will gain immediate
access to the Conversations section at iTerapi, ﬁnd a Welcome Message
from the assigned therapist and a request at the Notiﬁcation Centre to
book an e-consultation (audio, video or chat). The purpose of this ﬁrst
e-consultation is discussing the structure of the program, reporting the
baseline ﬁndings and tailoring the intervention according to partici-
pants' needs and preferences. Once therapists and participants reach an
agreement, the selected optional modules should be prescribed along
with the mandatory modules. Subsequently, access to the other sections
at the platform and speciﬁcally to the ﬁrst treatment module will be
granted. The following treatment modules should be assigned in a
weekly basis, with participants prompted to complete the modules in
approximately one week. If the participants fail to complete the mod-
ules in the speciﬁed time frame, a reminder is automatically sent by e-
mail/SMS. Within 24 h of module completion the therapists, based on
the reported outcomes, should assess participants' progress and de-
termine whether it is appropriate or not for the patients to proceed to
the next module. If so, the participants should receive access to the
following module. If not, therapists should instruct participants on what
needs to be completed to be able to advance to the next module. A mid-
test assessment (T1, approximately 1,5 months after treatment initia-
tion), using Cancer AAQ, should be performed after the completion of at
least 3 of the mandatory treatment modules, to assess treatment pro-
gress regarding psychological ﬂexibility. After iNNOVBC termination a
post-test assessment (T2, approximately 2,5 to 3 months after treatment
initiation) should be performed to assess the eﬃcacy of the
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intervention. At this point, WLC should be performing a second as-
sessment to be compared with the results yielded by the experimental
group and test the iNNOVBC eﬃcacy. This assessment will be used to
reassess the eligibility requirements of the WLC to cross-over to
iNNOVBC intervention. The same treatment and assessment protocol
should be implemented in the WLC for ethical reasons. This entails that
there will be no control group to compare with after T3 (3 months after
experimental group end of treatment).
3.6.7. Participant discontinuation from study intervention and/or study
participation
Participants may withdraw from iNNOVBC and/or the study at any
time and for any reason or be dropped from the study by the researcher
if a severe aggravation of the baseline symptoms occurs. In this case,
the participant should be referred to the respective Psychiatric/Psycho-
oncology Department at the study sites. The main reason for dis-
continuing iNNOVBC and/or the study must be registered at iTerapi.
Patients discontinuing prematurely iNNOVBC but willing to keep par-
ticipating in the study, should perform the protocoled follow-up as-
sessments. This information will be analysed to assess the feasibility
and adequacy of the program. If it's the participant intent to completely
withdraw from the study, the reason for withdrawal should be reported
and a ﬁnal assessment should be performed whenever the participant
agrees with it. When contact is lost with a participant, the research
team should contact the participant via telephone before acknowl-
edging him/her as lost to follow-up.
3.6.8. Participants and sites replacement
Lost to follow-up participants may be replaced to ensure an accep-
table number of evaluable participants in each study arm. However, the
replacement should be performed by re-opening the recruitment period
and it is not allowed to randomize a participating subject twice.
Additional sites may be included in the study if the current enrolled
sites fail to meet the established recruitment threshold. The research
protocol must be approved by the new site's board and ethical com-
mittee prior to inclusion in the study. Participating sites may be re-
placed due to excessively slow recruitment or protocol violation/non-
adherence.
3.6.9. Follow-up assessments
Long-term eﬀects will be examined by performing three follow-up
assessments in this study: T3 (3 months after end of treatment); T4
(6 months after end of treatment) and T5 (12 months after end of
treatment).
3.6.10. End of study
The end of the study will be reached when all participants from both
study arms have completed the ﬁnal follow-up assessments.
3.6.11. Project timeline
Fig. 2 describes this project timeline.
3.6.12. Data handling and storage
All data will be collected via iTerapi. The study sites will be re-
sponsible for data entry concerning clinical and socio-demographic
information. The remaining data will be entered by the participants.
The research team will be responsible for the data management and
quality control. Compliance with security requirements enforced by the
laws and regulations described on Section 3.6.1 will be ensured. All
sensitive data will be stored encrypted in the database. The key that
produced the code that allows the indirect identiﬁcation of the parti-
cipants will be deleted ﬁve years after the end of the study, as instructed
by Deliberação n. ° 1704/2015 (Deliberação da Comissão Nacional de
Protecção de Dados Aplicável aos tratamentos de dados pessoais efectuados
no âmbito de Investigação Clínica).
3.7. Statistical and economic analysis
3.7.1. Power and sample size
Considering previous randomized-controlled trials (RCT), sys-
tematic reviews and meta-analysis assessing the eﬀectiveness of in-
ternet-delivered treatments (Andersson and Cuijpers, 2009; Richards
and Richardson, 2012; Barak et al., 2008), a moderate eﬀect size (Co-
hen's d= 0.5), should be expected. Therefore, to capture an eﬀect size
0.5 as statistically signiﬁcant in a two-tailed test at alpha = 0.05 and a
power of (1-Beta) = 0.80, a minimum of 64 participants per Arm will
be required, as computed by G*Power 3.0.10 (Faul et al., 2007).
3.7.2. Statistical analysis plan
IBM SPSS for Windows will be used for all analysis. The exact ver-
sion of the software to be used will be reported in future publications.
Descriptive statistics will be calculated to characterize the study
sample. Potential baseline diﬀerences between groups regarding clin-
ical and socio-demographic variables and pre-treatment data will be
examined using independent samples t-test for continuous variables and
χ2 test for categorical variables. Non-signiﬁcant diﬀerences will con-
ﬁrm the success of randomization.
All data analysis will be performed according to the intention-to-
treat principle, where all randomized participants are included in the
analysis assuming missing data at random. A mixed models approach
instead of analysis of variance will be used for this purpose, as sug-
gested by Gueorguieva and Krystal (2004). This statistical approach is
considered to present advantages over traditional data analytic ap-
proaches for the analysis of repeated-measures data such as, the ability
to incorporate time-varying predictors, handle dependence among re-
peated observations in a ﬂexible manner, and to provide accurate es-
timates with missing data under unrestrictive missing data assumptions
(Hesser, 2015). The full information maximum likelihood estimation
method will be implemented.
Eﬀect sizes (Cohen's d) and a 95% conﬁdence interval will be cal-
culated to measure the magnitude of the treatment eﬀects for con-
tinuous outcomes, both within groups at post-intervention and follow-
up assessments compared to baseline, and between-groups using the
observed mean and pooled SD at post-treatment, and by the estimated
means from the mixed-model. The following formula for converting
standard error to standard deviation: SD = SE&times; sqrt(n) will be
used for this purpose. According to Cohen (Cohen, 1992), eﬀect
sizes< 0.2, between 0.2 and 0.5 and>0.8 are considered small,
moderate and large, respectively. A moderate eﬀect size (Cohen's
d = 0.5) is expected to be captured in this research.
Clinical signiﬁcance will be determined using Jacobson & Truax
method (Jacobson and Truax, 1991). This method comprises two op-
erations: the calculation of the Reliable Change Index (RCI) (the dif-
ference between a participant's pre-test and post-test scores, divided by
the standard error of the diﬀerence) and the calculation of the Cut-oﬀ C
value (a weighted midpoint between the means of the outcome at in-
terest). These products are then combined to categorize individuals in
one of the following categories: recovered (the participant has passed
Cut-oﬀ C and the RCI in the positive direction); improved (the partici-
pant has passed the RCI in the positive direction but not the Cut-oﬀ C);
unchanged (the participant did not pass either of the criterion); or de-
teriorated (the participant has passed the RCI in the negative direction)
(Lappalainen et al., 2014).
An independent statistician who is blind to the allocation will test
the research hypothesis.
3.7.3. Economic analysis plan
The economic analysis will be undertaken from a societal perspec-
tive, considering the intervention costs, direct costs (medical and non-
medical) and indirect costs during the study period. The intervention
costs refer to internet connection prices and time participants and
therapists spend using the program and the training/salary of the
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therapists. The costs related to software development and deployment
costs (“sunk costs”) will not be assessed. Direct costs concern to all
healthcare utilization (direct medical costs) and direct out-of-pocket
expenses incurred by the participants (non-medical direct costs).
Indirect costs are related to production losses namely, absenteeism
(being absent from work because of illness) and presenteeism (being
present at work while ill which may lead to reduced eﬃciency), both in
paid labour and in the domestic setting. Health service uptake and
production losses will be measured at T0, T2, T3, T4 and T5 based on
TIC-P.
The source for intervention costs will be based on market prices.
Economic costs due to direct medical costs will be obtained from
Portaria n.° 207/2017 de 11 de julho issued by the Portuguese Ministry
of Health and INFARMED prices; direct non-medical costs will be based
on market prices; and indirect costs will be extracted from the monthly
reports issued by Direcção-Geral de Estudos, Estatística e Planeamento
(DGEEP: http://www.dgeep.mtss.gov.pt) and SISED - Sistema de
Informação sobre Salários, Emprego e Duração do Trabalho database from
the Portuguese Ministry of Labour, Solidarity and Social Security. To
estimate indirect costs the human capital method will be used.
Considering that the timeframe of the present study is relatively short
(12 months), costs will not be corrected for inﬂation nor discounted.
iNNOVBC economic evaluation will encompass a cost-eﬀectiveness
analysis (CEA) and a cost-utility analysis (CUA). For the CUA, QALYs
will be calculated based on EuroQol EQ-5D-5L. Incremental cost-ef-
fectiveness and cost-utility ratios (ICERs) will be calculated by dividing
the diﬀerence in total costs between conditions (experimental and
WLC) by the diﬀerence in average outcomes between the two alter-
natives. Bootstrapping will be used to calculate 95% conﬁdence inter-
vals around the mean diﬀerence in total costs between the treatment
conditions and to estimate the uncertainty related to the ICERs. ICERs
will be depicted in cost-eﬀectiveness planes and sensitivity analyses will
be computed to determine the robustness of the results. ICER accept-
ability curves for a series of willingness-to-pay ceilings will also be
produced. Since there is no universally accepted ICER threshold or a
speciﬁc threshold adopted in Portugal, the most common cost-eﬀec-
tiveness threshold used in the United Kingdom (£20,000–30,000/QALY
or LYG) (Claxton et al., 2015) will be adopted to interpret the ﬁndings
of this economic evaluation.
4. Expected results
Results of this research will be published in accordance with
CONSORT-EHEALTH (Eysenbach, 2011) guidelines. It is anticipated
that iNNOVBC will show to be an eﬃcacious and cost-eﬀective method
to improve psychosocial outcomes such as anxiety, depression,
psychological ﬂexibility, fatigue, insomnia and sexual dysfunction in
breast cancer survivors as opposing to a WLC under TAU.
5. Discussion
Providing access to comprehensive, cost-eﬀective, patient-centred
survivorship care is currently a challenge in many health care systems,
and Portugal in no exception. Survival, in the breast cancer population,
has increased steadily and signiﬁcantly over the past years and deli-
vering psychosocial care to the “signiﬁcant minority” of survivors in
need is imperative (Beckjord et al., 2016). Innovative healthcare de-
livery models, where self-management internet-delivered interventions
are included, may prove crucial in overcoming organizational and ﬁ-
nancial barriers frequently associated to the traditional healthcare de-
livery model in the future, especially in countries where non-pharma-
cologic support is virtually absent in primary care, as is the case of
Portugal (Kleiboer et al., 2016).
To the best of our knowledge, this is the ﬁrst study assessing the
eﬃcacy and cost-eﬀectiveness of internet-delivered interventions
aiming at improving mild to moderate anxiety and depression in breast
cancer survivors, in Portugal. Post and Flanagan (2016), in a recent
integrative literature review identiﬁed 15 studies on the subject, of
which only 6 included RCT designs. Additionally, most studies were
conducted in the U.S, the Netherlands, Belgium, Canada and South
Korea and targeted a wide variety of outcomes, including: self-eﬃcacy,
empowerment, working memory, fatigue, distress, depression, patient-
provider communication, physical activity, symptom management, us-
ability, acceptability and patient satisfaction.
iNNOVBC aims at determining the acceptability, feasibility, eﬃcacy
and cost-eﬀectiveness of a guided, internet-delivered individually-tai-
lored ACT-inﬂuenced cognitive behavioural intervention designed to
improve psychosocial outcomes such as, anxiety, depression, psycho-
logical ﬂexibility, fatigue, insomnia, sexual dysfunction and HRQoL in
breast cancer survivors when compared to TAU in a WLC.
Consequently, an RCT design will be implemented to address the main
limitation identiﬁed in previous studies. A Pilot study will anticipate the
main study, to comply with user-centred development requirements
and test the intervention's feasibility. An economic evaluation of
iNNOVBC will be undertaken from a societal perspective, considering
intervention costs, direct medical costs, direct non-medical costs and
indirect costs during the study period.
It is expected that iNNOVBC will prove to be an eﬃcacious and cost-
eﬀective method in improving psychosocial outcomes in breast cancer
survivors, when compared to TAU in a WLC and that its conclusions will
inform the implementation of internet-delivered programs, in the fu-
ture. Additional strengths associated to this research are related to its
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underlying theoretical frameworks, ACT and CBT, proved to be ac-
ceptable approaches in the oncology and internet-interventions ﬁelds
(Andersson, 2016; Brown et al., 2016); its transdiagnostic, individually-
tailored and guided characteristics; the fact that it will intervene in the
sexual health of breast cancer survivors - a domain with high demand
for interventions but limited resources - and report on longitudinal
patient outcomes such as HRQoL.
This project may also encompass some limitations. The fact that, so
far, no other study reported on the eﬃcacy and cost-eﬀectiveness of
internet-delivered programs in the Portuguese population makes it
impossible to estimate on the acceptability, feasibility and adherence of
Portuguese breast cancer survivors to this type of programs. Therefore,
it can be challenging to recruit the number of participants needed to
conclude on the outcomes of this research and generalize the results to
the Portuguese population of breast cancer survivors. In order to
overcome this limitation, a multicentre study design was established
and to guarantee optimal usage of the program, the study intervention
was developed according to persuasive system development principles
(responsiveness, simplicity, ease of access and use, reduction, tunnel-
ling, tailoring, personalization, reminders, suggestion and professional
support) (Oinas-Kukkonen and Harjumaa, 2009). An additional lim-
itation to be appointed to this study, is related to the fact that it only
targets disease free BC survivors, not including participants with me-
tastatic disease or another important group of survivors, the family and
caregivers of breast cancer patients. The time frame available to im-
plement this project and its feasibility, informed this decision.
6. Conclusions
This research will yield evidence-based information on the accept-
ability, feasibility, eﬃcacy and cost-eﬀectiveness of iNNOVBC in breast
cancer survivors when compared to TAU in a WLC.
Its conclusions will contribute to understand the idiosyncrasies of
designing and implementing internet-delivered interventions in breast
cancer survivors.
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